Skip to main content

Veru Inc. (VERU)

NASDAQ: VERU · IEX Real-Time Price · USD
8.05
-0.04 (-0.49%)
After-hours:Oct 22, 2021 7:34 PM EDT
8.09
-0.25 (-3.00%)
At close: Oct 22, 4:00 PM
Market Cap645.75M
Revenue (ttm)57.36M
Net Income (ttm)-143,691
Shares Out79.73M
EPS (ttm)0.00
PE Ration/a
Forward PE117.65
Dividendn/a
Ex-Dividend Daten/a
Volume405,108
Open8.27
Previous Close8.34
Day's Range7.96 - 8.27
52-Week Range2.30 - 24.57
Beta0.64
AnalystsStrong Buy
Price Target24.40 (+201.6%)
Est. Earnings DateDec 8, 2021

About VERU

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2...

IndustryPersonal Products
IPO DateJul 19, 1990
CEOMitchell Steiner
Employees339
Stock ExchangeNASDAQ
Ticker SymbolVERU
Full Company Profile

Financial Performance

In 2020, Veru Inc.'s revenue was $42.59 million, an increase of 33.92% compared to the previous year's $31.80 million. Losses were -$18.97 million, 57.9% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Veru Inc. stock is "Strong Buy." The 12-month stock price forecast is 24.40, which is an increase of 201.61% from the latest price.

Price Target
$24.40
(201.61% upside)
Analyst Consensus: Strong Buy

News

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3 rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed, valid...

1 week ago - GlobeNewsWire

7 Top-Rated Pharmaceutical Stocks To Invest in for October

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first ...

Other symbols:CLSDINVAMTEXORMPUTHR
2 weeks ago - InvestorPlace

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Pr...

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, tod...

1 month ago - GlobeNewsWire

Veru to Present at Three Upcoming Healthcare Investment Conferences

MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, tod...

1 month ago - GlobeNewsWire

Why Veru Stock Vaulted Higher Today

An analyst raised his price target for the stock.

1 month ago - The Motley Fool

Why Veru Stock Blasted Higher on Friday

An analyst argues that the company has far more value than many realize.

Other symbols:OPY
1 month ago - The Motley Fool

Veru Stock Gains After Q3 Result Tops Estimates

Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2 prescription net revenues climbed 150% Y/Y t...

2 months ago - Benzinga

Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates

Veru Inc. (VERU) delivered earnings and revenue surprises of 50.00% and 26.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Veru: Q3 Earnings Insights

Shares of Veru (NASDAQ:VERU) rose 13.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 40.00% over the past year to ($0.03), which beat the estima...

2 months ago - Benzinga

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter

--Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs—

2 months ago - GlobeNewsWire

Earnings Outlook For Veru

On Thursday, August 12, Veru (NASDAQ:VERU) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

2 months ago - Benzinga

Earnings Preview: Veru Inc. (VERU) Q3 Earnings Expected to Decline

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th

MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, toda...

2 months ago - GlobeNewsWire

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastat...

MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, tod...

3 months ago - GlobeNewsWire

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resi...

--Sabizabulin is a novel oral androgen receptor transport disruptor-- -- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resista...

3 months ago - GlobeNewsWire

Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injec...

--VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --The Phase 2 clinical trial is expected to be completed by 2H calendar 2021--

4 months ago - GlobeNewsWire

Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients

Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent, in heavily pre-treated breast cancer pa...

4 months ago - Benzinga

Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels...

-- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ 40% AR ...

4 months ago - GlobeNewsWire

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration...

-- Sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing Phase 1b/2 study of...

4 months ago - GlobeNewsWire

Veru to Present at the Jefferies Virtual Healthcare Conference

MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today...

4 months ago - GlobeNewsWire

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 ...

-- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeti...

4 months ago - GlobeNewsWire

Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19

Veru Inc (NASDAQ: VERU) has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients. Sabizabulin an oral cytoskeleton disru...

5 months ago - Benzinga

Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Pat...

—Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities—

5 months ago - GlobeNewsWire

Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates

Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and -7.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Veru's FC2 Prescription Sales Boost Q2 Revenues

Veru Inc (NASDAQ: VERU) reported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago.

5 months ago - Benzinga